Valeant Isn't A Short-Term Fix


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Things seem to keep getting worse and worse for Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and its shareholders, including last week’s deep guidance cut. Barclays analyst Douglas Tsao believes Valeant’s new management team is taking steps in the right direction, but the journey will be a long one for the battered company.

No Shortcuts

“While last week’s cut to expectation was not unanticipated given the change in leadership and the realities of script trends in recent months, the magnitude clearly showed a lot of work remains to be done,” Tsao explained.

At the very least, Valeant seems to have eased concerns over near-term liquidity, but Tsao is still leery of the company’s large long-term debt load.

He noted Valeant could further address its debt issues by selling non-core assets, but this strategy would also cut back on the company’s free cash flow.

Barclays believes the fact that Valeant has had so many problems with its Walgreens Boots Alliance Inc (NASDAQ: WBA) deal, including losing money on some prescriptions, is an indication that the deal is poorly-structured and will likely not solve the company’s distribution problems.

Not All Bad

It’s not all bad news for Valeant, however, as Bausch & Lomb is firing on all cylinders and should get boost from product launches throughout the remainder of the year.

Barclays lowered its 2016 EPS estimate for Valeant to $6.77 but maintains its Equal Weight rating and $34 price target for the stock.

Disclosure: The author holds no position in the stocks mentioned.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorBiotechLong IdeasHealth CareReiterationTop StoriesAnalyst RatingsTrading IdeasGeneralBarclaysBausch & LombDouglas Tsao